Edition:
United States

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

23.50EUR
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
€23.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,792
52-wk High
€54.27
52-wk Low
€20.20

Latest Key Developments (Source: Significant Developments)

Celyad SA H1 Operating Loss At EUR 18.8 Million
Thursday, 23 Aug 2018 01:06am EDT 

Aug 23 (Reuters) - Celyad SA ::H1 OPERATING LOSS EUR 18.8 MILLION VERSUS LOSS OF EUR 13.7 MILLION YEAR AGO.H1 REVENUE EUR 2.5 MILLION VERSUS EUR 3.5 MILLION YEAR AGO.H1 LOSS OF THE PERIOD EUR 18.5 MILLION VERSUS LOSS OF EUR 14.4 MILLION YEAR AGO.  Full Article

Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update
Wednesday, 16 May 2018 03:29am EDT 

May 16 (Reuters) - CELYAD SA ::ANNOUNCED ON TUESDAY Q1 BUSINESS AND THINK TRIAL UPDATES.GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT.THOSE TWO PATIENTS EACH EXPERIENCED A GRADE 5 EVENT THAT WAS DEEMED UNRELATED TO ADMINISTRATION .CYAD-01 IS CURRENTLY BEING EVALUATED AS A STAND-ALONE INVESTIGATIONAL THERAPY IN THE THINK TRIAL WITH RELAPSED REFRACTORY AML AND CRC PATIENTS.CYAD-01 IS ALSO BEING EVALUATED FOR BEING ADMINISTERED AFTER LYMPHODEPLETION PRECONDITIONING - RELEVANT DEPLETHINK AML AND CRC TRIALS TO BE INITIATED IN COMING WEEKS.IN MAY 2018, ACHIEVED IMPORTANT MILESTONE IN ITS CYAD-01 CLINICAL STRATEGY BY DOSING FIRST METASTATIC CRC PATIENTS IN THE LINK AND SHRINK TRIALS.NO DRUG RELATED TOXICITY WAS OBSERVED IN THE FIRST PATIENTS OF BOTH SHRINK AND LINK TRIALS.ENDED Q1 WITH EUR 25.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.CONFIRMS EXISTING CASH AND CASH EQUIVALENTS AND SHORT TERM INVESTMENTS ARE SUFFICIENT TO FUND EXPENSES UNTIL END-Q1 2019.  Full Article

Celyad FY EBIT Loss Widens to 52.9 Million Euros
Friday, 23 Mar 2018 02:45am EDT 

March 23 (Reuters) - CELYAD ::ANNOUNCED ITS FY RESULTS ON THURSDAY .FY NET LOSS FOR THE YEAR 56.4 MILLION EUROS VS LOSS OF 23.6 MILLION EUROS YEAR AGO .FY EBIT IS LOSS OF 52.9 MILLION EUROS VS LOSS OF 25.6 MILLION EUROS YEAR AGO.CASH AND SHORT-TERM DEPOSITS WERE EUR 34 MILLION AT END DEC. .FOR 2018, EXPECTS TO RECEIVE ADDITIONAL SUBLICENSING INCOME FROM STRATEGIC PARTNERS AND REASONABLE INCREASE OF OPERATING EXPENSES.OPERATING EXPENSES IN 2018 TO BE MAINLY RESEARCH AND DEVELOPMENT EXPENSES .  Full Article

Celyad ends Q3 with EUR 40 million in cash, confirms previous guidance
Friday, 17 Nov 2017 01:00am EST 

Nov 17 (Reuters) - CELYAD SA ::ENDED THE QUARTER WITH EUR 40 MILLION IN CASH.CONFIRMS ITS PREVIOUS GUIDANCE THROUGH TO THE FIRST HALF 2019.  Full Article

Celyad SA files for mixed shelf offering of up to $250 mln
Thursday, 31 Aug 2017 04:57pm EDT 

Aug 31 (Reuters) - Celyad SA :Celyad SA files for mixed shelf offering of up to $250 million - SEC filing ‍​.  Full Article

Celyad H1 operating loss narrows to 13.7 million euros
Tuesday, 29 Aug 2017 01:00am EDT 

Aug 29 (Reuters) - CELYAD SA ::H1 OPERATING LOSS EUR 13.7 MILLION VERSUS LOSS OF EUR 17.2 MILLION YEAR AGO.H1 NET LOSS EUR 14.4 MILLION VERSUS LOSS OF EUR 16.9 MILLION YEAR AGO.ENDS THE FIRST HALF OF 2017 WITH EUR 69 MILLION IN CASH AND SHORT-TERM DEPOSITS.  Full Article

Celyad announces new agreements with Celdara medical and Dartmouth College
Friday, 4 Aug 2017 01:01am EDT 

Aug 4 (Reuters) - CELYAD SA ::CELYAD ANNOUNCES NEW AGREEMENTS WITH CELDARA MEDICAL AND DARTMOUTH COLLEGE.‍ONGOING CLINICAL TRIAL DEVELOPMENT BOOSTS CELYAD'S CONFIDENCE IN FUTURE OF ITS ONCOLOGY ASSETS​.‍CELYAD TO RECEIVE AN INCREASED SHARE OF FUTURE REVENUES IN EXCHANGE FOR $25M WORTH OF CASH AND CELYAD SHARES​.‍CELYAD HAS AMENDED ITS EXISTING AGREEMENTS WITH CELDARA MEDICAL, LLC AND DARTMOUTH COLLEGE​.‍UNDER AMENDED AGREEMENTS CELYAD WILL RECEIVE AN INCREASED SHARE OF FUTURE REVENUES GENERATED BY THESE ASSETS, INCLUDING REVENUES FROM ITS SUBLICENSEES​.‍IN RETURN, CELYAD WILL PAY CELDARA MEDICAL LLC AND DARTMOUTH COLLEGE AN UPFRONT PAYMENT OF $12.5 MILLION (EUR 10.6 MILLION) AND $12.5 MILLION WORTH OF CELYAD SHARES​.‍SHARES WILL BE PRICED AT EUR 32.35​.  Full Article

BioLife Solutions executes supply agreement with Celyad for CryoStor
Monday, 31 Jul 2017 06:30am EDT 

July 31 (Reuters) - BioLife Solutions Inc :Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers.Biolife Solutions Inc - has executed a long term supply agreement with Celyad.Biolife Solutions Inc - co's CryoStor clinical grade cell freeze media is incorporated into Celyad's manufacturing process.  Full Article

Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells
Tuesday, 30 May 2017 01:00am EDT 

May 30 (Reuters) - CELYAD SA ::CELYAD OBTAINS ADDITIONAL US PATENT FOR ALLOGENEIC CANCER TREATMENT BASED ON TCR-DEFICIENT CAR-T CELLS.  Full Article

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents
Tuesday, 2 May 2017 01:00am EDT 

May 2 (Reuters) - Celyad Sa : :Celyad grants to Novartis <<>> a non-exclusive license for its allogeneic TCR-Deficient CAR-T Cells Patents.This license agreement is related to two targets currently under development by Novartis.Under the terms of the agreement Celyad receives an upfront payment and is eligible to receive success based clinical, regulatory and commercial milestone payments.If all success based milestones are achieved, Celyad is eligible to receive payments, including the upfront payment, totalling $96 million.In addition, Celyad will receive single digit royalties based on net sales of the licensed target associated products.Novartis has the option to extend the agreement to additional targets and/or to convert its license into an exclusive license. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.  Full Article

BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering

* 1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE